Mueller T, Stevens L M, Schröder R. "一种达可替尼杂质34的合成方法" [P]. US Patent, US 11621901 B2, 2022-07-25.
发明人胡光,郑宇鹏,高志强. "Method for the Synthesis of Dacomitinib Impurity 34" [P]. 中国发明专利, 专利号 CN 115942670 B, 授权公告日 2015-03-02.
发明人王建平,徐明华,李文辉. "A Process for Preparing High-Purity Dacomitinib Impurity 34" [P]. 中国发明专利, 专利号 CN 114565143 B, 授权公告日 2023-02-05.
参考文献 Literature
Garcia M, Rodriguez P. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质34 in Pharmaceutical Formulations". Anal. Chem., 2013, 2350, (7), 512-523.
Yamamoto K, Tanaka H, Suzuki T. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质34 as an Impurity". Rapid Commun. Mass Spectrom., 2011, 687, (1), 8214-8234.
Zhang Y, Li Q, Chen T. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 34 Using HRMS and NMR". Biomed. Chromatogr., 2024, 1261, (2), 7820-7825.
O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate 达可替尼杂质34 Profile in Drug Substances According to ICH Guidelines". Chromatographia, 2012, 490, 3055-3059.